Clinical TrialsSearch results
Number of results: 70225
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- ZilvEr PTX for tHe Femoral ArterY and Proximal Popliteal ArteRy. -Prospective multicenter registry-
- Peripheral artery disease
- ZEPHYR Study Group
- 2012-07-13
Other
- Novel DCB for Coronary Artery Disease Trial
- Coronary Artery Disease
- Zeon Medical Inc. Business Development Depertment
- 2019-04-05
Other
- Rituxan injection drug use-results survey in patients with complicated nephrotic syndrome
- nephrotic symdrome
- Zenyaku Kogyo, Co., Ltd.
- 2014-08-29
Other
- Rituxan injection drug use-results survey in ABO-incompatible liver transplantation recipients
- ABO-incompatible liver transplantation
- Zenyaku Kogyo, Co., Ltd.
- 2016-03-07
Other
- Rituxan injection drug use-results survey in ABO-incompatible kidney transplantation recipients
- ABO-incompatible kidney transplantation
- Zenyaku Kogyo, Co., Ltd.
- 2016-09-01
Other
- Rituxan injection specific drug use-results survey
- Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA)
- Zenyaku Kogyo Co., Ltd.
- 2013-09-01
Other
- Post-marketing clinical study of rituximab monotherapy at eight weekly infusions in relapsed or refractory patients with indolent B-cell non-Hodgkin's lymphoma
- Indolent non Hodgkin's lymphomas
- Zenyaku Kogyo Co., Ltd.
- 2010-01-05
Other
- Phase III study for evaluating efficacy and safety of desensitization based on IDEC-C2B8 in living donor kidney transplantation recipients with pre-formed anti-HLA antibody and/or donor-specific antibody. Phase III study for evaluating efficacy, safety and pharmacokinetics of pre-transplant administration of FK506 or FK506E(MR4) for 7 to 28 days in living donor kidney transplantation recipients.
- Living donor kidney transplantation recipients with pre-formed anti-HLA antibody and/or donor-specific antibody.
- ZENYAKU KOGYO CO., LTD.
- 2018-10-23
Other
- Phase III study for evaluating efficacy and safety of a combination treatment of IDEC-C2B8 with steroid pulse therapy and plasmapheresis for antibody-mediated rejection after kidney transplant.
- Antibody-mediated rejection (ABMR) after living or cadaveric kidney transplant.
- ZENYAKU KOGYO CO., LTD.
- 2018-10-23